Loading company…
Sydnexis develops treatments intended to slow childhood myopia.
Sydnexis is a clinical-stage biopharmaceutical company developing treatments for childhood myopia. Its pipeline includes SYD-101, an investigational low-dose atropine sulfate eye solution intended to slow myopia progression in children. Founded in 2014 and based in California, the company raised USD 999,807 million in Series B funding in April 2024. Its leaders include president Patrick Johnson and CEO Perry J. Sternberg.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in